Coya Therapeutics Inc
coyatherapeutics.comWhat Do They Do?
Develops therapies that enhance regulatory T-cell function, including biologics, exosomes and cell therapies, for patients with neurodegenerative, autoimmune and metabolic diseases.
10-K for FY2025, filed Mar 16, 2026We are a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells…View ↗
Our core focus is developing therapies to target Treg dysfunction. Treg dysfunction has been identified as an important pathophysiological…View ↗
Our strategy is to discover, develop, manufacture, and commercialize proprietary medicinal products that enhance the function of Tregs. We…View ↗
How Do They Make Money?
Dr. Reddy’s pays Coya for research and development services under their agreement; Coya can also receive upfront license fees, milestone payments when regulatory or commercial milestones are achieved, and royalties tied to licensed-product sales.
10-K for FY2025, filed Mar 16, 2026The Company’s revenues have been solely generated through the DRL Development Agreement (Note 10), which falls under the scope of ASC Topic…View ↗
Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the…View ↗
Milestone Payments: At the inception of an agreement that includes regulatory or commercial milestone payments, the Company evaluates…View ↗
Royalties: If the Company is entitled to receive sales-based royalties from its collaborator, including milestone payments based on the…View ↗
$7.9M
-
10-K for FY2025, filed Mar 16, 2026
$7.9M ↗
Who Are Their Customers?
Coya’s revenue comes through a development and license agreement with Dr. Reddy’s, a collaborator on COYA 302 for ALS.
10-K for FY2025, filed Mar 16, 2026
Do Revenues Turn Into Profits?
No. It lost $21.2M in FY2025.
10-K for FY2025, filed Mar 16, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 11, 2026
−$6.6MView ↗
- ▲ +9% (Loss)
- vs −$6.1M in Q2 FY2025
-
Apr 2, 2026
Executive Chairman Howard Berman resigned from the board
Mark H. Pavao was appointed as an independent director to fill the board vacancy.
Sources
8-K, filed Apr 2, 2026
On March 29, 2026, Dr. Howard Berman resigned from the board of directors (the “Board”) of Coya Therapeutics, Inc. (the “Company”) and from…View ↗
Lead-program focus
The older report presented a low-dose interleukin biologic for frontotemporal dementia alongside a combination biologic for ALS and other conditions. The latest report centers development on the combination biologic for ALS and frontotemporal dementia.
10-K for FY2022, filed Mar 29, 2023 10-K for FY2025, filed Mar 16, 2026
A more specific pipeline plan
The older report described plans to expand the pipeline with additional biologics and combinations. The latest report identifies another biologic combination for inflammatory diseases and plans to seek partners or grants to advance it.
10-K for FY2022, filed Mar 29, 2023Expand our pipeline by identifying and developing additional product candidates and identifying additional target indications. We intend to…View ↗
Who Do They Compete With?
Competes with Ionis Pharmaceuticals, Neurizon Therapeutics, Alchemab Therapeutics, Athira Pharma, NeuroSense Therapeutics, Amylyx Pharmaceuticals, Medicinova, Clene Nanomedicine, Amgen, Nektar Therapeutics, Merck, Xencor, Cue Biopharma, Moderna, ILTOO Pharma, Abata Therapeutics, Sonoma Biotherapeutics, Sangamo Therapeutics, TRex Bio, and Mozart Therapeutics
10-K for FY2025, filed Mar 16, 2026Clinical-stage competitor companies developing drugs for ALS include: Ionis Pharmaceuticals (in collaboration with Biogen), Neurizon…View ↗
Loading...
